Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intestinal Disorders Clear all
Completed Phase 1 Interventional

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Jun 25, 2026, 5:25 PM EDT
Terminated Phase 2 Interventional Results available

Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure

NCT04604275
View directory record Official record
Conditions
Short Gut Syndrome
Interventions
Sucrase, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

NCT03597581
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic
Interventions
ompenaclid, FOLFIRI, Bevacizumab, FOLFOX regimen
Drug
Lead sponsor
Inspirna, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
17
States / cities
Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Effects of Open-label vs Double-blind Treatment in IBS

NCT02802241
View directory record Official record
Conditions
Irritable Bowel Syndrome, Placebo Effect, Placebos, Peppermint Oil
Interventions
placebo, peppermint oil
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

NCT04006301
View directory record Official record
Conditions
Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
JNJ-74699157
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sarasota, Florida • Tampa, Florida • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

Fecal Transplant for Ulcerative Colitis

NCT03948919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal microbiota, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

NCT00200200
View directory record Official record
Conditions
Hepatic Metastases, Colon Cancer, Rectal Cancer
Interventions
Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Active, not recruiting Phase 1 Interventional

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051
View directory record Official record
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 5:25 PM EDT
Withdrawn Not applicable Interventional

Hybrid Transvaginal-Transabdominal Endoscopic Surgery

NCT01039129
View directory record Official record
Conditions
Gallstones, Appendicitis, Pelvic Pain
Interventions
Endoscopic Cholecystectomy, Endoscopic Appendectomy, Endoscopic Peritoneoscopy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Jun 25, 2026, 5:25 PM EDT
Active, not recruiting Phase 1 Interventional

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

NCT04046445
View directory record Official record
Conditions
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
Interventions
ATP128, BI 754091, VSV-GP128
Drug
Lead sponsor
Amal Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Recruiting No phase listed Observational

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 25, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional

Confronting Cancer as a Community

NCT06063928
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Usual Care Educational Materials, Intervention Educational Materials
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 25, 2026, 5:25 PM EDT
Terminated Phase 1Phase 2 Interventional

SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer

NCT00361244
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
SU011248, Irinotecan, Cetuximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC

NCT04890054
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Fecal Immunochemical Test, Interview, Patient Navigation
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,696 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

NCT00574353
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study

NCT01412372
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 3 Interventional Results available

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

NCT03945019
View directory record Official record
Conditions
Crohn's Disease
Interventions
CT-P13 SC (Infliximab), Placebo SC
Biological · Other
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02947165
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cancer
Interventions
NIS793, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jun 25, 2026, 5:25 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

NCT06654037
View directory record Official record
Conditions
Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Fluorouracil, Radiologic Imaging Procedure
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Irvine, California • Orange, California • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 25, 2026, 5:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease

NCT06215222
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Healthy, Functional Bloating, Functional Gastrointestinal Disorders
Interventions
Microbiota Sampling
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova

NCT01433471
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Trichuris suis ova
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 72 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Jun 25, 2026, 5:25 PM EDT
Not listed Not applicable Interventional

Prebiotics in Rectal Cancer

NCT05516641
View directory record Official record
Conditions
Rectal Cancer
Interventions
Soluble Corn Fiber, Maltodextrin
Dietary Supplement
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Jun 25, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment

NCT00942266
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
fluorouracil, leucovorin calcium, vorinostat, pharmacological study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Jun 25, 2026, 5:25 PM EDT